Sara López-Tamargo

Sara López-Tamargo

Auto-generated profile, based on publicly available information

Sara López-Tamargo

Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
PBPablo Bousquets-Muñoz
Pablo Bousquets-Muñoz
ADAnder Diaz-Navarro
Ander Diaz-Navarro
FNFerran Nadeu
Ferran Nadeu
ASAna Sánchez-Pitiot
Ana Sánchez-Pitiot
SLSara López-Tamargo
Sara López-Tamargo
XPXose S. Puente
Xose S. Puente
Current somatic mutation callers are biased against repetitive regions, preventing the identification of potential driver alterations in these loci. We developed a mutation caller for repetitive regions, and applied it to study repetitive non protein-coding genes in more than 2200 whole-genome cases. We identified a recurrent mutation at position c.28 in the gene encoding the snRNA U2. This mutation is present in B-cell derived tumors, as well as in prostate and pancreatic cancer, suggesting U2 c.28 constitutes a driver candidate associated with worse prognosis. We showed that the GRCh37 reference genome is incomplete, lacking the U2 cluster in chromosome 17, preventing the identification of mutations in this gene. Furthermore, the 5′-flanking region of WDR74, previously described as frequently mutated in cancer, constitutes a functional copy of U2. These data reinforce the relevance of non-coding mutations in cancer, and highlight current challenges of cancer genomic research in characterizing mutations affecting repetitive genes.

21 November 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
Elena LlanoElena Llano
Elena Llano
ATAnne Laure Todeschini
Anne Laure Todeschini
NFNatalia Felipe-Medina
Natalia Felipe-Medina
MCMaria Daniela Corte-Torres
Maria Daniela Corte-Torres
YCYazmine B. Condezo
Yazmine B. Condezo
RVReiner A. Veitia
Reiner A. Veitia
Adult-type granulosa cell tumors (AGCT) are the most common type of malignant ovarian sex cord–stromal tumors. Most AGCTs carry the somatic variant c.402C>G (p.C134W) affecting the transcription factor FOXL2. Germline dominant variants in FOXL2 are responsible for blepharophimosis syndrome, which is characterized by underdevelopment of the eyelid. In this work, we generated a mouse model harboring the C134W variant of FOXL2 to evaluate in vivo the poorly understood oncogenic role of FOXL2. The mutation was dominant regarding eyelid hypoplasia, reminiscent of blepharophimosis syndrome. Interestingly, Foxl2+/C134W female mice had reduced fertility and developed AGCTs through a progression from abnormal ovaries with aberrant granulosa cells to ovaries with stromal hyperplasia and atypia and on to tumors in adut mice. The genes dysregulated in mouse AGCTs exhibited the hallmarks of cancer and were consistent with a gain-of-function of the mutated allele affecting TGFβ signaling. A comparison of these data with previous results on human AGCTs indicated similar deregulated pathways. Finally, a mutational analysis of mouse AGCT transcriptomic data suggested the absence of additional driver mutations apart from FOXL2-C134W. These results provide a clear in vivo example in which a single mutational hit triggers tumor development associated with profound transcriptomic alterations. Significance: A newly generated mouse model carrying a FOXL2 mutation characteristic of adult-type granulosa cell tumors shows that FOXL2 C134W shifts the transcriptome towards a signature of granulosa cell cancer and drives tumorigenesis.

1 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SLSara López-Tamargo
Sara López-Tamargo
JFJavier Fernández-Mateos
Javier Fernández-Mateos
PBPablo Bousquets-Muñoz
Pablo Bousquets-Muñoz
LLLaura Llaó-Cid
Laura Llaó-Cid
FNFerran Nadeu
Ferran Nadeu
XPXose S Puente
Xose S Puente
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal mature B lymphocytes in peripheral blood, bone marrow, lymphoid tissues, and extranodal sites. Genes involved in RNA splicing such as SF3B1 and U1 are frequently mutated in CLL, leading to altered splicing and generation of tumor neoepitopes. To study the impact of these mutations on the tumor microenvironment (TME), we have developed a comprehensive single-cell atlas of unmutated CLL encompassing 26 bone marrow and lymph node tumor samples from 23 U-CLL patients with mutations in U1 (n=7), SF3B1 (n=8), or without mutations in splicing genes (n=10). We observed high intra-tumor heterogeneity, discerning 12 transcriptional programs, one linked to the U1 g.A3>C mutation and characterized by NFKB hyperactivation. T cell and NK compartments exhibited site- and mutation-specific enrichment, with increased CD4 + regulatory cells (Treg) and CD8 + exhausted cells in lymph nodes, while U1 -mutant tumors showed increased CD8 + cytotoxic activity, with a predominance of effector-like CD8 + cells. Single-cell T cell receptor sequencing revealed clonotype expansion in U1 -mutated tumors, particularly in CD8 + effector and exhausted cells, suggesting a neoantigen-driven immune response. Cell-to-cell interaction analysis identified CD44 as a key mediator in U1 -mutated tumors, showing pro-B survival interactions as those involving MIF-CD44-CD74. Furthermore, interactions between CD80 on CLL cells and CTLA4 on Tregs and CD8 + exhausted were upregulated, reflecting an immunosuppressive phenotype associated with U1 mutated CLL. These findings highlight the complex interplay between mutations in CLL and the TME, offering novel avenues for alternative therapeutic strategies for U-CLL with mutations in U1 .

31 March 2023
Verified
Other
Open access
Elena LlanoElena Llano
Elena Llano
ATAnne Laure Todeschini
Anne Laure Todeschini
NFNatalia Felipe-Medina
Natalia Felipe-Medina
MCMaria Daniela Corte-Torres
Maria Daniela Corte-Torres
YCYazmine B. Condezo
Yazmine B. Condezo
RVReiner A. Veitia
Reiner A. Veitia

31 March 2023
Verified
Other
Open access
Elena LlanoElena Llano
Elena Llano
ATAnne Laure Todeschini
Anne Laure Todeschini
NFNatalia Felipe-Medina
Natalia Felipe-Medina
MCMaria Daniela Corte-Torres
Maria Daniela Corte-Torres
YCYazmine B. Condezo
Yazmine B. Condezo
RVReiner A. Veitia
Reiner A. Veitia

31 March 2023
Verified
Other
Open access
Elena LlanoElena Llano
Elena Llano
ATAnne Laure Todeschini
Anne Laure Todeschini
NFNatalia Felipe-Medina
Natalia Felipe-Medina
MCMaria Daniela Corte-Torres
Maria Daniela Corte-Torres
YCYazmine B. Condezo
Yazmine B. Condezo
RVReiner A. Veitia
Reiner A. Veitia